Prime Medicine, Inc. (PRME) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Maurice Raycroft
Jefferies LLC, Research Division

Hi, everyone. My name is Maury Raycroft and I’m one of the biotech analysts at Jefferies. I’d like to welcome Allan Reine, CEO of Prime Medicine. Thanks so much for joining us today, Allan.

Allan Reine
CEO & Director

Thanks for having us here.

Maurice Raycroft
Jefferies LLC, Research Division

And we’re doing a fireside chat format. So maybe for those who are new to the story, if you can give a brief intro to the company.

Allan Reine
CEO & Director

Yes. So Prime Medicine is a company that’s focused on progressing our technology, which is Prime Editing. This is a revolutionary gene editing technology, sort of the 1-minute pitch without going into all the details around the technology is think about this as the way I like to say it is it’s the safest way to edit the genome versus any other type of gene editing technology that’s come before this, but it’s also the most versatile way to edit the genome.

So think of Prime Editing as we can do any type of edit that any other technology can do, but we can also do so much more, right? So we can do large insertions. We can do — fix all these different types of edits that other technologies can’t do. For example, in Wilson disease, going after what are called transversion edits, et cetera. So again, the most versatile and the safest gene editing technology, we think that exists out there.